实用肝脏病杂志2011，Vol.14Issue(3)：190-191,2.DOI:10.3969/j.issn.1672-5069.2011.03.011
拉米夫定联合阿德福韦酯初始治疗慢性乙型肝炎患者临床观察
Clinical study on antiviral efficacy of de novo lamivudine and adefovir dipivoxil treatment in patients with chronic hepatitis B
冯静 1伦秀英 1贾德兴 1李雪莲 1陈建红 1李萍1
作者信息
- 1. 261041,山东省潍坊市人民医院感染病科
- 折叠
摘要
Abstract
Objective To analyze the clinical effect of lamivudine (LAM)in initial combination with adefovir dipivoxil (ADV)in treatment of patients with chronic hepatitis B (CHB). Methods One hundred and twenty CHB patients were randomly divided into two groups. The patients in one group (n=60)were subjected to treatment with LAM alone for 24 weeks and when HBV DNA were not negative,the patients were switched to combination of LAM and adefovir dipivoxiI(ADV)subsequently,while the patients in other group (n=60)were given LAM in combination with ADV de novo. Results The rates of serum HBV DNA loss in the two groups were not significantly different (P＞0.05),and the rates of serum HBV DNA in patients with HBV DNA≥107 copies/ml at week 4 and 16 were not significantly different (P＞0.05),hut at week 24 (x2=4.573,P＜0.05)and week 48 were significantly different (x2=4.289,P＜0.05). Conclusions Patients with high serum viral load should be treated by initial combination therapy in order to achieve better results.关键词
慢性乙型肝炎/拉米夫定/阿德福韦酯/初始优化治疗引用本文复制引用
冯静,伦秀英,贾德兴,李雪莲,陈建红,李萍..拉米夫定联合阿德福韦酯初始治疗慢性乙型肝炎患者临床观察[J].实用肝脏病杂志,2011,14(3):190-191,2.
